<DOC>
	<DOCNO>NCT02793505</DOCNO>
	<brief_summary>This study aim well characterize risk link metformin use pregnancy , use prospective multicentric cohort design enable large sample size , evaluate rate birth defect first trim exposure , well several pregnancy relate outcome .</brief_summary>
	<brief_title>Safety Metformin Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Exposed group : expose metformin ( Anatomical Therapeutic Chemical A10BA02 ) time pregnancy ( i. e. time conception week 42 last menstrual period ( LMP ) ) . Reference group : time pregnancy expose metformin , insulin hypoglycaemic agent . expose follow known major teratogen major fetotoxicant : acitretin , isotretinoin , mycophenolate , thalidomide , valproic acid , angiotensinII receptor blocker ( use 2nd 3rd trimester ) , ACE inhibitor ( use 2nd 3rd trimester ) , ( b ) follow treatment indication cod : malignancy ( MedDRA code : malignant unspecified tumor ( SMQ 20000091 ) , ICD10 : C00D09 ) ) malignancy relate condition ( MedDRA : SMQ 20000092 ) , ICD10 : C00D09 ) . lose followup</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>metformin</keyword>
	<keyword>pregnancy outcome</keyword>
	<keyword>birth defect</keyword>
	<keyword>spontaneous abortion</keyword>
	<keyword>pharmacoepidemiology</keyword>
</DOC>